Fisher & Paykel Healthcare Corporation Limited (FPH.AX)
ValueMarkers Composite Index
699% above intrinsic value ($2)
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems worldwide. It also provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company offers Airvo 2, a humidified nasal high flow system; Optiflow, a nasal high flow therapy; and F&P 850 System, a noninvasive and invasive ventilation system. In addition, it provides infant respiratory products, such as resuscitation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy products. Further, the company offers hospital products, including humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, humidifiers, and accessories. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.
Deep Dive Analysis
DCF Analysis
Intrinsic value estimate, margin of safety, and key valuation metrics.
Piotroski F-Score
9-point financial strength test across profitability, leverage, and efficiency.
Quality Triple Check
Piotroski F-Score + Altman Z-Score + Beneish M-Score combined assessment.
Valuation Analysis
Complete multiples breakdown - P/E, P/B, EV/EBITDA, yield metrics, and intrinsic value.